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Abstract
Background: Although anaemia is a common complication of advanced chronic kidney disease (CKD), knowledge of quality
of care and management practices in specialist clinics varies. We examined anaemia practices at specialist nephrology clin-
ics within the Irish health system and evaluated the opinions of practicing nephrologists.
Methods: A multicentre cross-sectional study was conducted at specialist nephrology clinics across six geographic regions
in Ireland. Clinical characteristics and treatment practices were evaluated in a sample of 530 patients with CKD. An accom-
panying national survey questionnaire captured opinions and treatment strategies of nephrologists on anaemia
management.
Results: The prevalence of anaemia [defined as haemoglobin (Hb)<12.0 g/dL] was 37.8%, which increased significantly with
advancing CKD (from 21% to 63%; P<0.01) and varied across clinical sites (from 36% to 62%; P<0.026). Iron deficiency (ID)
was present in 46% of all patients tested and 86% of them were not on treatment. More than 45% of anaemic patients were
not tested for ID. Respondents differed in their selection of clinical guidelines, threshold targets for erythropoiesis-stimulat-
ing agent (ESA) and intravenous iron therapy and anaemia management algorithms were absent in 47% of the clinics. The
unexpectedly low rates of ESA use (4.7%) and iron therapy (10.2%) in clinical practice were in contrast to survey responses
where 63% of nephrologists indicated ESA therapy initiation when Hb was<10.0 g/dL and 46% indicated commencement of
iron therapy for ferritin<150 ng/mL.
Conclusion: This study highlights substantial variability in the management of anaemia and ID at specialist nephrology
clinics with low testing rates for ID, high rates of anaemia and ID and underutilization of effective treatments. Variability in
the adoption and implementation of different clinical guidelines was evident.
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Introduction
Chronic kidney disease (CKD) is a major public health epidemic
that is associated with increased morbidity and mortality and
substantially lower quality of life [1–5]. A fundamental objective
in the care pathway of all CKD patients is to tackle modifiable
risk factors in order to halt or slow progression to end-stage renal
disease (ESRD), increase patient survival and improve overall pa-
tient physical well-being. A highly prevalent and relatively easily
identifiable risk factor is anaemia associated with CKD. In the
USA, for example, anaemia is twice as prevalent in CKD patients
as in the general population. Moreover, the prevalence of an-
aemia increases as CKD progresses, affecting almost half of those
with Stage 5 CKD [6]. A substantial body of evidence incriminates
anaemia as a risk multiplier for major medical conditions, includ-
ing coronary heart disease and stroke [7, 8]. Moreover, prospect-
ive epidemiological studies have linked anaemia with the
development of left ventricular hypertrophy and left ventricular
systolic dysfunction [9], along with higher rates of hospitaliza-
tion, poorer quality of life and greater mortality [4, 10, 11].
Therefore, early identification and correction of anaemia is an
important component of care provision for patients with
advanced CKD.
Despite the increasing availability of a broad range of inves-
tigations and treatment strategies, it is striking that anaemia re-
mains underdiagnosed and undertreated in routine clinical
practice [12, 13]. Two recent studies have uncovered an unex-
pectedly high prevalence of anaemia among non-dialysis CKD
patients and surprisingly low rates of the use of anaemia treat-
ments [12, 13]. A study by Minutolo et al. [12] conducted in Italy
estimated that 44% of CKD patients attending renal clinics were
anaemic and that the proportion remained virtually unchanged
after 6 months of follow-up. A further study by Cases-Amenos et
al. [13] in Spain found an even higher percentage with anaemia
(58.5%) and significant undertreatment of iron deficiency (ID).
These studies would suggest that significant gaps remain in the
management of anaemia among CKD patients attending spe-
cialist clinics and that a critical need exists for more effective
implementation pathways. For example, it is unclear at the pre-
sent time to what extent CKD patients are investigated for the
presence of anaemia at specialist nephrology clinics. Second, it
is equally uncertain whether the lack of evidence-based proto-
cols and their implementation may in part be responsible for
any observed deficiency in care provision. Third, it remains to
be proven whether the treatment delivered at the coalface is
concordant with the views and expectations of the supervising
nephrologist.
To provide a better understanding of anaemia management,
we conducted a multicentre audit of clinical practices at specialist
renal clinics in Ireland. We also explored concurrently the opin-
ions of supervising nephrologists on the use of clinical guidelines
and thresholds for intervention from a survey questionnaire.
Materials and methods
Study design
We conducted a multicentre cross-sectional study of con-
secutive adult non-dialysis CKD patients treated at specialist
nephrology clinics during the first 2 weeks of December 2012
and 2013. The 18 specialist nephrology clinics were widely
distributed across six health regions in the Republic of
Ireland (West, Midwest, Northwest, Midlands, East and
Southeast). A standardized data collection tool was used to
capture clinical information from medical case records, la-
boratory information systems and physician clinic letters.
Data were recorded on demographic and clinical characteris-
tics, including primary cause of kidney disease, comorbid
medical conditions, prescribed medications and laboratory
values recorded within the previous 3 months [or within
6 months for laboratory values for iron studies, parathyroid
hormone (PTH), iron studies, lipids and haemoglobin A1c
(HbA1c)]. Patients<18 years of age or on dialysis were excluded.
Anaemia was primarily defined as Hb<12.0 g/dL, although add-
itional definitions were also used to characterize the extent of an-
aemia according to the following Hb thresholds: Hb<13 g/dL for
men and<12 g/dL for women according to the World Health
Organization (WHO) criteria, Hb<11 g/dL and Hb<10 g/dL. ID was
defined as serum ferritin<100 ng/mL and/or transferrin saturation
(TSAT)<20%. The estimated glomerular filtration rate (eGFR) was
calculated using the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) equation [14].
The clinical study was accompanied by a survey question-
naire of adult nephrologists registered by the Irish and UK
Medical Councils and practising in the North and South of
Ireland. The survey questionnaire captured information on the
use of clinical guidelines for CKD management in routine clin-
ical practice, threshold values of laboratory parameters to
prompt clinical intervention and the opinions of nephrologists
on suggested management strategies. The study was approved
by the Ethics Committee of University Hospital Limerick.
Statistical analysis
Descriptive statistics were used to describe the baseline charac-
teristics of the study population. Categorical variables are pre-
sented as numbers and percentages, whereas continuous
variables are presented as mean (SD) or median [interquartile
range (IQR)]. The prevalence of anaemia according to specified
Hb thresholds was computed by the stage of CKD and across
health regions. Comparisons across groups were made using
chi-square and Fisher’s exact tests for categorical variables.
Student’s t-test and analysis of variance were used for continu-
ous variables. Correlates of anaemia (Hb <12 g/dL) were identi-
fied in a series of separate univariate logistic regression models.
A final multivariate logistic regression was constructed to iden-
tify the relative contributions of demographic, clinical and treat-
ment factors with the presence of anaemia. Associations were
expressed as odds ratios (ORs) and 95% confidence intervals
(CIs). The adequacy of the models was tested using the Hosmer
and Lemeshow goodness-of-fit test and the discriminative
index using the C-statistic. All analyses were performed using
SAS version 9.4 software (SAS Institute, Cary, NC, USA).
Results
Baseline characteristics of the study population
The baseline characteristics of the study population and by GFR
category are shown in Table 1. The average age was 57 (SD 18)
years, 56% were men and the majority were white Irish (95%).
The principal causes of CKD were hypertension (27.2%), glomer-
ulonephritis (17.7%) and diabetes (12.6%), although for a large
proportion the causes were classified as unknown (13.4%). The
average eGFR was 48 (SD 28) mL/min/1.73 m2 overall and just
under a third (31%) had advanced CKD (Stages 4–5). Patients
with more advanced CKD had significantly lower Hb and serum
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Table 1. Baseline characteristics of the study population by stage of CKD
n Overall cohort Stages 1–2a Stage 3a Stages 4–5a P-value
Demographic
Age (years, mean (SD) 510 57.1 (18.3) 48.1 (15.5) 59.3 (16.8) 65.5 (17.1) <0.001
Men (%) 293 55.3 55.6 59.8 56.0 0.706
Race (%)
White Irish 492 92.8 91.4 96.6 96.4 0.049
White Irish traveller 2 0.4 0.7 0.0 0.0 0.055
White other 12 2.3 1.4 2.8 2.9 0.050
Asian 2 0.4 0.7 0.6 0.0 0.053
Other 9 1.7 5.7 0.0 0.7 0.054
Cause of CKD (%)
Hypertension 144 27.2 22.9 24.6 34.8 0.055
Diabetes 67 12.6 8.3 15.1 17.0 0.064
Glomerulonephritis 94 17.7 24.3 14.5 14.9 0.047
Autosomal dominant PKD 33 6.2 4.9 8.9 5.0 0.267
Hereditary 14 2.6 3.5 3.4 0.7 0.261
Other 172 32.5 0.0 0.0 0.0 0.610
Not known 71 13.4 11.1 10.1 16.3 0.233
Kidney biopsy (%) 79 14.9 19.4 14.5 13.5 0.348
Comorbid conditions (%)
Diabetes 111 20.9 17.4 24.1 28.3 0.117
Hypertension 382 72.1 73.6 80.1 84.1 0.116
Cancer 34 6.4 7.4 8.4 6.5 0.820
Heart failure 22 4.2 1.7 4.2 7.2 0.111
Thyroid disease 49 9.2 5.8 12.0 13.0 0.107
Stroke/TIA 22 4.2 3.3 4.2 6.5 0.490
COPD 22 4.2 3.3 4.2 5.8 0.609
Peripheral vascular disease 38 7.2 3.3 10.2 10.9 0.042
Coronary heart disease 76 14.3 9.1 15.8 23.9 0.004
Obesity 29 5.5 4.1 4.8 8.7 0.262
Gout 59 11.1 5.7 15.2 15.9 0.013
Hypercholesterolaemia 131 24.7 23.0 30.3 32.4 0.209
Depression 20 3.8 5.0 3.6 5.1 0.799
Arthritis 29 5.5 5.0 7.2 4.3 0.538
Osteoporosis 31 5.8 5.8 9.6 2.9 0.050
Current or ex-smoker 53 10.0 12.4 12.0 8.7 0.572
Physical measurements, mean (SD)
Weight (kg) 408 80.6 (17.4) 79.8 (15.8) 79.8 (17.5) 82.0 (19.4) 0.445
Pulse 301 75.1 (16.2) 75.6 (13.1) 73.6 (13.4) 75.7 (19.2) 0.920
Systolic BP (mmHg) 495 137.7 (19.6) 131.7 (16.6) 138.8 (19.0) 141.5 (21.7) <0.001
Diastolic BP (mmHg) 495 77.5 (13.3) 78.7 (13.7) 77.6 (12.9) 76.7 (12.3) 0.221
Laboratory parameters, mean (SD)
eGFR (mL/min/1.73m2) 464 48.5 (27.9) 82.7 (19.4) 43.5 (8.3) 19.9 (6.1) <0.001
Haemoglobin (g/dL) 461 12.6 (1.9) 13.5 (1.7) 12.7 (1.8) 11.6 (1.7) <0.001
Ferritin (ng/L) 163 251.6 (334.6) 244.7 (401.2) 174.4 (195.0) 311.7 (366.0) 0.326
TSAT ratio (%) 132 26.6 (13.2) 27.4 (11.4) 29.6 (15.9) 25.2 (12.6) 0.443
Folate (nmol/L) 97 39.6 (142.3) 63.2 (189.5) 10.1 (6.3) 27.9 (113.9) 0.230
Vitamin B12 (nmol/L) 124 451.5 (271.1) 418.9 (201.0) 480.1 (404.1) 471.4 (189.9) 0.386
Calcium (mmol/L) 417 2.4 (0.2) 2.4 (0.2) 2.4 (0.1) 2.3 (0.2) <0.001
Albumin (g/L) 364 41.1 (5.6) 42.4 (5.6) 41.6 (5.0) 39.3 (6.2) <0.001
Phosphate (mmol/L) 388 1.1 (0.3) 1.0 (0.2) 1.1 (0.2) 1.3 (0.3) <0.001
PTH (pg/mL) 166 131.7 (128.6) 70.4 (42.8) 107.5 (126.8) 157.4 (133.7) 0.001
Total cholesterol (mmol/L) 199 4.6 (1.4) 4.9 (1.4) 4.6 (1.0) 4.4 (1.6) 0.053
LDL cholesterol (mmol/L) 126 2.6 (1.2) 2.8 (1.3) 2.4 (0.7) 2.5 (1.5) 0.293
HDL cholesterol (mmol/L) 128 1.4 (0.5) 1.4 (0.5) 1.5 (0.5) 1.3 (0.4) 0.591
Triglycerides (mmol/L) 196 3.9 (21.2) 1.8 (1.4) 4.4 (23.2) 5.5 (28.2) 0.376
HbA1c (mmol/mol) 89 48.4 (23.4) 47.5 (15.1) 43.4 (14.3) 49.1 (27.0) 0.904
Urine tests
Protein:creatinine ratio 139 139.3 (246.6) 49.0 (71.3) 157.5 (344.8) 210.6 (223.6) 0.002
Albumin:creatinine ratio 53 101.4 (211.3) 22.7 (28.1) 93.4 (239.2) 205.9 (270.6) 0.019
Medications
ACE-I 121 22.8 26.4 25.7 16.3 0.066
ARB 96 18.1 18.8 20.1 18.4 0.921
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albumin and significantly higher phosphate and PTH hormone
concentrations.
Prevalence of anaemia
The average Hb concentration in the overall cohort was
12.661.9 g/dL. According to the WHO definition, the overall
prevalence of anaemia in the entire cohort was 49% and
increased significantly from 28% in CKD Stages 1–2 to 76% in
CKD Stages 4–5 (P< 0.001) (Figure 1). The prevalence of anaemia,
irrespective of what definition was used, increased significantly
with advancing stage of CKD (P< 0.001) and this pattern corres-
ponded to a decrease in mean Hb levels from 13.5 g/dL in Stages
1–2 to 11.6 in Stages 4–5 (P< 0.001). Using Hb< 12.0 g/dL as the
target threshold for defining anaemia, the prevalence of an-
aemia increased significantly from 21% in CKD Stages 1–2 to
63% in CKD Stages 4–5 (P< 0.001). The prevalence of anaemia ac-
cording to the WHO criteria varied significantly across health
care region, from 36% in the Northwest to 62% in the Southeast
(P¼ 0.026), although there was no statistically significant differ-
ence in mean Hb levels across regions (12.3 g/dL in Southeast
and 13.1 g/dL in Northwest (P¼not significant) (Figure 2 and
Table 2). Similarly, serum ferritin levels and TSAT concentra-
tions did not vary significantly across regions, as shown in
Table 2.
The univariate associations of anaemia defined as
Hb<12.0 g/dL are shown in Supplementary Table S1. In the final
multivariate model (Table 3), the presence of anaemia
(Hb<12.0 g/dL) was associated with lower levels of kidney func-
tion [OR 1.11 (95% CI 1.04–1.18)] per 5 mL/min/1.73 m2 lower, fe-
male sex [OR 3.43 (95% CI 2.00–5.86)], younger age [OR 1.46 (95%
CI 1.26–1.85) for age group 18–40 versus age 41–60 years (refer-
ent)], hyperphosphataemia [OR 1.22 (95% CI 1.09–1.37)] per
0.1 mmol/L higher and treatment with erythropoiesis-stimulat-
ing agent (ESA) or iron therapy [OR 5.82 (95% CI 1.95–17.36)]. The
C-statistic for the model was 0.82.
Prevalence of ID
The overall prevalence of ID among anaemic patients using
WHO criteria was 30%, with the highest prevalence in pa-
tients with Stages 4–5 CKD (Table 4). Not surprisingly, the pro-
portion of iron-deficient patients varied according to the Hb
threshold; increasing from 5.2% with Hb<10 g/dL to 30.2%
using WHO criteria. The mean serum ferritin and TSAT for
the entire cohort were 251.6 ng/L (SD 334.6) and 26.6% (SD
13.2), respectively (Tables 1 and 2). The prevalence of ID var-
ied across health regions, with the highest in the Midlands
(50%) and the lowest in the Northwest (10%) (P¼ 0.01), and the
pattern was similar using a lower Hb threshold of<12 g/dL
(see Supplementary Table S2).
Screening for ID in CKD patients
Of 436 CKD patients with WHO anaemia, 113 (25.9%) were tested
for ID (Table 5). The prevalence of ID screening was lowest in
CKD Stages 1–2 patients at 12.8%, increasing to 50.8% in CKD
Stages 4–5 patients (P< 0.001). The prevalence of ID screening
did not differ across health regions.
Treatment patterns of anaemia and ID
Only 8.7% of clinic patients were receiving either iron therapy or
ESA therapy and utilization rates were similar across health re-
gions. ESA rates increased from 0.7% in CKD Stages 1–2 to 12.1%
in CKD Stages 4–5 (P< 0.001) (Table 1). According to WHO-
Table 1. (continued)
n Overall cohort Stages 1–2a Stage 3a Stages 4–5a P-value
ACE-I and ARB 12 2.3 2.1 3.9 0.7 0.164
Aspirin 181 34.2 25.0 34.1 45.4 0.001
Iron therapy (oral or i.v.) 54 10.2 2.1 8.9 19.1 <0.001
ESA therapy 25 4.7 0.7 3.4 12.1 <0.001
PKD, polycystic kidneys; TIA, transient ischaemic attack; COPD, chronic obstructive pulmonary disease; BP, blood pressure; LDL, low-density lipoprotein; HDL, high-
density lipoprotein; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker. ESA, erythropoietin stimulating agent
aeGFR (estimated glomerular filtration rate per CKD-EPI equation) was available for 464 patients .
Fig. 1. Prevalence of anaemia by CKD stage.
Fig. 2. Anaemia prevalence across health care regions. NS¼non-significant
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Table 2. Baseline characteristics of the study cohort by geographic region
Overall West Mid-West North-West Midlands East South-East
P-valuen (n¼530) (n¼120) (n¼ 103) (n¼70) (n¼52) (n¼ 150) (n¼35)
Demographic
Age (years), mean (SD) 510 57.1 (18.3) 56.5 (19.6) 57.2 (17.5) 59.0 (15.6) 63.9 (18.7) 54.2 (18.8) 55.4 (17.5) 0.216
Men (%) 293 55.3 49.6 56.3 63.8 49.0 56.0 65.7 0.309
Race (%)
White Irish 492 92.8 93.3 96.0 94.3 96.1 96.5 94.3 0.123
White Irish traveller 2 0.4 0.8 0.0 0.0 0.0 0.7 0 0.127
White other 12 2.3 4.2 1.0 5.7 3.9 0.0 0.0 0.125
Asian 2 0.4 0.8 0.0 0.0 0.0 0.7 0.0 0.130
Other 9 1.7 0.8 3.3 0.0 0.0 2.1 5.7 0.123
Cause of CKD (%)
Hypertension 144 27.2 21.7 9.7 32.9 23.1 42.0 28.6 <0.001
Diabetes 67 12.6 14.2 6.8 12.9 32.7 8.7 11.4 0.001
Glomerulonephritis 94 17.7 30.0 19.4 12.9 13.5 9.3 22.9 0.001
Autosomal dominant PKD 33 6.2 5.0 7.8 8.6 3.8 5.3 8.6 0.759
Hereditary 14 2.6 1.7 4.9 7.1 3.8 0.0 0.0 0.007
Other 172 32.5 23.3 27.2 48.6 42.3 33.3 28.6 0.006
Not known 71 13.4 14.2 30.1 7.1 13.5 6.7 2.9 <0.001
Kidney biopsy (%) 79 14.9 17.5 25.2 7.1 13.5 10.7 11.4 0.011
Comorbid conditions (%)
Diabetes 111 20.9 22.4 20.6 21.7 44.7 17.8 25.0 0.017
Hypertension 382 72.1 86.9 67.6 64.1 87.2 74.8 83.3 0.006
Cancer 34 6.4 1.9 3.9 8.7 21.3 7.4 8.3 0.002
Heart failure 22 4.2 4.7 6.9 8.8 0.0 0.0 16.7 <0.001
Thyroid disease 49 9.2 10.3 8.8 8.7 21.3 6.7 16.7 0.107
Stroke/TIA 22 4.2 7.5 4.9 7.2 8.5 0.0 0.0 0.005
COPD 22 4.2 5.6 5.9 10.1 0.0 2.2 0.0 0.072
Peripheral vascular disease 38 7.2 3.7 11.8 8.7 10.6 5.2 16.7 0.078
Coronary heart disease 76 14.3 15.9 20.6 13.0 27.7 8.2 20.8 0.014
Obesity 29 5.5 0.0 5.9 18.8 8.5 3.7 4.2 <0.001
Gout 59 11.1 16.8 19.6 4.3 17.0 5.2 13.0 0.001
Hypercholesterolaemia 131 24.7 38.1 14.7 42.9 42.6 16.3 17.4 <0.001
Depression 20 3.8 6.5 3.9 1.4 6.4 3.7 0.0 0.550
Arthritis 29 5.5 4.7 3.9 15.9 17.0 0.7 0.0 <0.001
Osteoporosis 31 5.8 3.7 7.8 18.8 10.6 0.7 0.0 <0.001
Current or ex-smoker 53 10.0 0.0 19.6 14.5 21.3 9.6 0.0 <0.001
Physical measurements, mean (SD)
Weight (kg) 408 80.6 (17.4) 79.5 (18.4) 81.3 (16.0) 80.7 (17.6) 81.7 (19.0) 80.2 (17.5) 79.2 (20.0) 0.641
Pulse 301 75.1 (16.2) 71.5 (14.9) 77.5 (17.3) 76.5 (16.7) 73.8 (15.5) 76.1 (15.8) 73.1 (14.0) 0.743
Systolic BP (mmHg) 495 137.7 (19.6) 136.4 (17.9) 137.6 (20.1) 139.5 (18.8) 143.0 (23.3) 135.0 (19.7) 142.5 (17.2) 0.331
Diastolic BP (mmHg) 495 77.5 (13.3) 78.5 (11.3) 77.0 (11.7) 76.8 (11.6) 75.3 (15.1) 78.4 (16.4) 77.0 (10.5) 0.429
Laboratory parameters, mean (SD)
eGFRa (mL/min/1.73 m2) 464 48.5 (27.9) 43.9 (24.2) 45.8 (29.3) 46.7 (23.8) 46.0 (28.8) 52.1 (30.2) 64.1 (28.5) 0.118
Haemoglobin (g/dL) 461 12.6 (1.9) 12.5 (2.1) 12.7 (1.9) 13.1 (1.7) 12.6 (1.8) 12.3 (1.8) 12.3 (1.8) 0.166
Ferritin (ng/L) 163 251.6 (334.6) 272.0 (303.4) 210.2 (223.5) 375.5 (488.7) 139.3 (192.0) 179.4 (236.5) 269.5 (187.4) 0.730
TSAT ratio (%) 132 26.6 (13.2) 23.3 (11.8) 24.1 (7.7) 31.1 (10.2) 20.8 (20.3) 27.8 (14.4) 25.4 (18.4) 0.327
Folate (nmol/L) 97 39.6 (142.3) 72.8 (207.9) 13.8 (8.5) 8.8 (4.7) 8.7 (5.1) 44.1 (152.4) 44.0 (NA) 0.548
Vitamin B12 (nmol/L) 124 451.5 (271.1) 445.4 (168.8) 510 (244.1) 603.8 (426.0) 384.5 (154.4) 376.2 (244.5) 575.0 (NA) 0.113
Calcium (mmol/L) 417 2.4 (0.2) 2.3 (0.1) 2.3 (0.2) 2.3 (0.2) 2.4 (0.1) 2.4 (0.2) 2.4 (0.2) <0.001
Albumin (g/L) 364 41.1 (5.6) 41.6 (7.1) 36.4 (5.2) 43.2 (4.2) 43.5 (3.4) 41.0 (3.3) 41.1 (6.4) <0.001
Phosphate (mmol/L) 388 1.1 (0.3) 1.1 (0.3) 1.3 (0.3) 1.1 (0.3) 1.1 (0.2) 1.1 (0.3) 1.2 (0.1) <0.001
PTH (pg/mL) 166 131.7 (128.6) 130.2 (95.3) 207.8 (189.5) 89.0 (50.4) 108.3 (137.2) 117.3 (106.2) NaN (NA) 0.004
Total cholesterol (mmol/L) 199 4.6 (1.4) 4.7 (1.9) 5.2 (1.5) 4.3 (0.8) 4.1 (0.9) 4.6 (1.3) 5.1 (0.9) 0.110
LDL cholesterol (mmol/L) 126 2.6 (1.2) 2.5 (1.6) 2.8 (1.4) 2.5 (0.7) 2.3 (0.8) 2.7 (1.3) 2.8 (0.6) 0.739
HDL cholesterol (mmol/L) 128 1.4 (0.5) 1.4 (0.6) 1.4 (0.6) 1.4 (0.4) 1.2 (0.3) 1.0 (0.2) 1.5 (0.6) 0.066
Triglycerides (mmol/L) 196 3.9 (21.2) 1.6 (0.8) 1.5 (0.8) 1.6 (0.8) 2.1 (1.4) 8.0 (35.1) 1.7 (1.3) 0.232
HbA1c (mmol/mol) 89 48.4 (23.4) 46.5 (15.2) 55.9 (25.8) 32.0 (26.7) 57.4 (19.1) 53.1 (37.4) 55.0 (14.2) 0.770
Urine tests
Protein:creatinine ratio 139 139.3 (246.6) 302.6 (406.2) 173.1 (171.7) 67.2 (134.2) NA (NA) 120.8 (176.1) 67.9 (28.8) 0.566
Albumin:creatinine ratio 53 101.4 (211.3) 170.6 (276.9) 0.6 (NA) 3.4 (3.0) 51.4 (70.1) 37.7 (47.7) 37.4 (52.8) 0.874
Medications (%)
ACE-I 121 22.8 25.8 15.5 35.7 17.3 20.7 25.7 0.044
ARB 96 18.1 24.2 10.7 14.3 21.2 16.7 28.6 0.057
ACE-I and ARB 12 2.3 1.7 0.0 4.3 1.9 3.3 2.9 0.300
(continued)
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defined anaemia, 9.7% of patients were treated with ESA and
utilization rates were higher at each lower Hb threshold: 12.4%
for Hb<12 g/dL, 16.9% for Hb<11 g/dL and 21.4% for Hb<10 g/dL.
The use of iron treatments [oral or intravenous (i.v.)] was
equally low at 10.2% and increased from 2.1% in Stages 1–2 pa-
tients to 19.1% in Stages 4–5 patients (P< 0.001 (Table 1). Among
iron-deficient patients, only 14.1% were receiving iron treat-
ments (Supplementary Table S3). Among iron-replete patients
(ferritin>100 ng/mL and/or TSAT>20%), only 11.1% were
treated with iron therapy.
Response of nephrologists to survey questionnaire on
anaemia management
Forty-nine (83%) of 59 nephrologists responded to the survey
questionnaire. There was substantial variation in the use of
clinical guidelines across participating clinic sites, with the UK
Renal Association guidelines being the most popular (41%) fol-
lowed by the Kidney Disease: Improving Global Outcomes
(KDIGO; 33%) and Kidney Disease Outcomes Quality Initiative
(KDOQI; 17%) (P< 0.001) (Figure 3). With regard to ID correction,
67% and 47% of respondents identified a TSAT of<20% and a
ferritin of<150 ng/mL, respectively, as target minimum thresh-
olds for the initiation of i.v. iron therapy. The threshold haemo-
globin for initiation of ESA therapy also varied, with 62.5% of
nephrologists reporting a threshold limit of<10.0 g/dL, whereas
6, 19 and 13% of nephrologists reported alternative thresholds
of 10.5, 9.5, and 9.0 g/dL, respectively. Most respondents (75%)
identified Hb values of 10–12 g/dL as the preferred target range.
Surprisingly, 47% of nephrologists reported an absence of CKD
anaemia algorithms at outpatient clinics.
Discussion
In this national audit of anaemia management among non-
dialysis CKD patients, we observed unexpectedly high rates of
anaemia and ID coupled with low screening rates and signifi-
cant undertreatment at specialist nephrology clinics. The high
rates of ID among clinic patients were in contrast with the rela-
tively low utilization rates of either oral or i.v. iron therapy.
Furthermore, differences in treatment patterns were observed
across participating centres, suggesting differences in clinical
practice. In support of this variability, our national survey found
that nephrologists differed in their choice of clinical guidelines
for CKD management, varied in their selection of Hb target
thresholds for ESA and iron prescribing and a large proportion
failed to adopt anaemia algorithms to guide clinical practice.
To the best of our knowledge, this is the first Irish study to
explore practice patterns in the management of anaemia
among non-dialysis CKD patients. It also sought to understand
variation in real-world practice by exploring provider attitudes
and behaviours through a focused national nephrologist survey.
Despite tremendous advances in our understanding of
CKD-associated anaemia, along with the introduction and im-
plementation of evidence-based anaemia guidelines, we dis-
covered high rates of anaemia and ID among patients with CKD.
The prevalence of CKD-associated anaemia in our study was
Table 2. (continued)
Overall West Mid-West North-West Midlands East South-East
P-valuen (n¼530) (n¼120) (n¼ 103) (n¼70) (n¼52) (n¼ 150) (n¼35)
Aspirin 181 34.2 31.7 30.1 35.7 46.2 31.3 45.7 0.165
Iron therapy (oral or i.v.) 54 10.2 11.7 13.6 8.6 13.5 6.7 8.6 0.435
ESA therapy 25 4.7 5 2.9 5.7 7.7 4 5.7 0.749
PKD, polycystic kidneys; TIA, transient ischaemic attack; COPD, chronic obstructive pulmonary disease; BP, blood pressure; LDL, low-density lipoprotein; HDL, high-
density lipoprotein; ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker, ESA, erythropoietin stimulating agent, NA¼not available.
aeGFR (estimated glomerular filtration rate per CKD-EPI equation) was available for 464 patients. NA¼not available.
Table 3. Correlates of anaemia (Hb<12.0 g/dL) expressed as adjusted
Odds Ratios (ORs)
Parameter
Adjusted
OR (95% CI) P-value
Age (18–40 versus 41–60 years) 1.46 (1.26–1.85) 0.0252
Women (versus men) 3.43 (2.01–5.86) <0.0001
Iron and/or ESA therapy
(yes versus no)
5.82 (1.95–17.36) 0.0016
Intervention for anaemia
at clinic (yes versus no)
5.52 (1.42–21.52) 0.0138
Phosphate (per 0.1 mmol/L higher) 1.22 (1.09–1.37) 0.0005
eGFRa (per 5 mL/min lower) 1.11 (1.04–1.18) 0.0015
n¼327 in final model, C-statistic 0.818.
aeGFR per CKD-EPI equation [14].
Table 4. Prevalence [n (%)] of ID among anaemic patients by CKD
stage
CKD
Stages 1–2
CKD
Stage 3
CKD
Stages 4–5 Total P-value
na (n¼41) (n¼ 50) (n¼ 81) (n¼ 172)
Hb< 10 g/dL 1 (2.4) 1 (2.0) 7 (8.6) 9 (5.2) 0.245
Hb< 11 g/dL 5 (12.2) 6 (12.0) 21 (25.9) 32 (18.6) 0.073
Hb< 12 g/dL 8 (19.5) 9 (18.0) 27 (33.3) 44 (25.6) 0.097
WHO definitionb 10 (24.4) 13 (26.0) 29 (35.8) 52 (30.2) 0.344
Totalc 19 (46.3) 23 (45.1) 38 (45.2) 80 (45.5) 1.000
aNumber of patients with available Hb, iron studies and eGFR.
bWHO criteria: Hb<13 g/dL for men and<12 g/dL for women.
cIrrespective of anaemia status.
Table 5. Prevalence n (%) [n (%)] of ID testing among anaemic patients
by CKD stage
Total
CKD
Stages 1–2
CKD
Stage 3
CKD
Stages 4–5 P-value
na (%) (n¼ 436) (n¼ 133) (n¼ 171) (n¼132)
Hb< 10 g/dL 19 (4.4) 2 (1.5) 6 (3.5) 11 (8.3) 0.023
Hb< 11 g/dL 59 (13.5) 6 (4.5) 13 (7.6) 40 (30.3) <0.001
Hb< 12 g/dL 95 (21.8) 13 (9.8) 22 (12.9) 60 (45.5) <0.001
WHO definitionb 113 (25.9) 17 (12.8) 29 (17.0) 67 (50.8) <0.001
Totalc 176 (37.9) 41 (28.5) 51 (28.5) 84 (59.6) <0.001
aNumber of patients with available Hb and eGFR.
bWHO criteria: Hb<13 g/dL for men and<12 g/dL for women.
cIrrespective of anaemia status; eGFR was available on a total of 464 patients.
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comparable to the reported rates from several international
studies irrespective of the definition of anaemia [11–13]. While
we estimated anaemia prevalence at 38.4% (using a Hb thresh-
old<12 g/dL), a US study of 5222 adult CKD patients using the
same definition reported an even higher prevalence of 47.7%
[15]. Similarly, the MICENAS I study reported an even higher
prevalence of 58.8% among 503 Spanish patients with Stages 3–
5 CKD using the WHO criteria, and exceeded our estimate of
49.5% [13]. Using a lower Hb threshold of<11 g/dL, a study from
Japan by Akizawa et al. [16] reported a prevalence of 33%, which
again was substantially higher than our estimate of 19.3%.
These findings would suggest that the prevalence of CKD-
associated anaemia remains quite substantial despite the avail-
ability of iron and ESA replacement therapies. The disparity in
prevalence estimates may be attributable to differences in the Hb
thresholds used to define anaemia, differences in clinical prac-
tice relating to the use and implementation of clinical guidelines
and differences in screening and treatment rates for ID.
A unique feature of our study was the inclusion of a detailed
provider questionnaire that assessed the clinical strategies with
regard to CKD anaemia management in the context of pub-
lished clinical guidelines. The findings from this survey would
suggest that variability in clinical practice patterns across sites
may be due in part to differences in the adoption and interpret-
ation of different sets of clinical guidelines [17–20]. From the
survey, 41% of nephrologists reported use of the Renal
Association Standards guidelines, whereas 33% reported adop-
tion of KDIGO guidelines. It is noteworthy that these guidelines
differ significantly with respect to the definition of anaemia
[KDIGO adopts WHO criteria (Hb<13 g/dL for men and<12 g/dL
for women)], whereas the UK Renal Association uses a lower Hb
threshold of 11 g/dL] and consequently these different thresh-
olds will influence the timing of and extent to which anaemia is
screened for. We also noted considerable variability in thresh-
old values of ID indicators that prompted initiation of i.v. iron
therapy. About half the surveyed nephrologists would start i.v.
iron therapy with ferritin<150 ng/mL, a threshold value that
was higher than that used in our definition of ID (<100 ng/mL),
and an even larger percentage (68%) would initiate i.v. iron for a
TSAT <20%. Similarly for ESA initiation, the threshold values
Fig. 3. Opinions of Irish nephrologists on anaemia management practices from national survey questions 1-6. Renal Association, UK Renal Association Guidelines;
KDIGO, Kidney Disease Improving Global Outcomes; KDOQI, Kidney Disease Outcomes Quality Initiative; Irish, Irish Chronic Kidney Disease Guidelines; CARI, Caring
for Australians with Renal Impairment; EBPG, European Best Practice Guidelines.
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for Hb differed among nephrologists, with almost two-thirds of
respondents choosing an Hb<10.0 g/dL as the threshold value
for ESA initiation. Although clinical guidelines were established
to improve clinical care and avoid potential harm, the inherent
variations across different sets of guidelines for a specific dis-
ease may lead to greater variability in care patterns and deliv-
ery. These findings would suggest the need for greater
harmonization of international clinical guidelines and clearer
implementation strategies.
The combination of a multicentre audit coupled with a na-
tional nephrologist survey allowed us the opportunity to com-
pare ‘what is being said to what is being done’ in clinical
practice. This study uncovered a number of shortcomings with
regard to screening practices and treatment strategies for an-
aemia management in CKD. For example, only 21% of those
with Hb<12 g/dL had iron studies performed within the 6-
month period prior to the captured clinic visit (Supplementary
Table S3). Furthermore, although testing rates improved as an-
aemia became more severe, they remained unacceptably low,
as only 68% (19 of 28) of patients with Hb<10.0 g/dL were tested.
These low testing rates also extended to treatment practices.
Only 8.7% of patients were on ESA or iron therapy. We also
observed a high degree of inertia to anaemia therapy. Only a
third of patients with Hb<10.0 g/dL were on iron (oral or i.v.) or
ESA therapy. Even more striking was the fact that 85.9% of iron-
deficient patients were not on iron therapy. These findings are
not unique to the Irish health system. Minutolo et al. [12] re-
ported that up to 75.7% of iron-deficient patients did not receive
iron therapy and up to 36% of anaemic patients (Hb<9.5 g/dL)
were not on ESA. In the MICENAS I study, only 53% of iron-defi-
cient patients were treated with iron supplements [13]. These
studies would suggest that treatment inertia is common in spe-
cialist CKD clinics. There are several reasons that may explain
these trends in practice. First, residual uncertainty continues re-
garding the optimal timing of ESA initiation in non-dialysis CKD
patients. Second, the evidence from randomized clinical trials
in CKD that targeting Hb values in the normal range did not
translate into clinical benefit but is in fact associated with
increased risk of harm is equally important [21–24]. These fac-
tors may have dampened the level of enthusiasm for a more ag-
gressive approach to anaemia management and prescribing of
ESA agents. On the other hand, evidence has now emerged that
repletion of iron stores can improve Hb levels, delay the need
for ESA and improve quality of life [25–27].
Our study is not without limitations. The cross-sectional de-
sign of this study lacks a longitudinal dimension, therefore es-
tablishment of the chronology of trends of laboratory data as
well as treatment interventions was not possible. A further limi-
tation was the reliance on medical records for data extraction in
a retrospective manner. Notwithstanding these limitations, this
study included a detailed description of patient characteristics,
including testing rates of ID and treatment interventions.
Furthermore, the study was multicentre, with participation
from large specialist clinics across Ireland, thus strengthening
the generalizability. Moreover, the burden of anaemia was
explored according to several clinically relevant and guideline-
recommended Hb thresholds. Finally, and equally important,
the inclusion of a national survey facilitated a better under-
standing of provider attitudes and allowed us to gain deeper in-
sights into guideline interpretation and thereby shed light on
potential areas of improvement.
Although anaemia is a well-recognized complication of CKD,
our study found suboptimal management (both investigation
and treatment) in a large proportion of CKD patients receiving
specialist care. The lack of a single set of clinical guidelines
coupled with low utilization rates of anaemia algorithms may
be contributory factors. Low treatment rates did not correspond
with the views of Irish nephrologists on treatment thresholds.
This study demonstrates that there is substantial room for im-
provement. The adoption of electronic alert systems to improve
the screening and recognition of patients at risk, the implemen-
tation of specific algorithms to manage CKD-associated an-
aemia at clinics and the greater utilization of anaemia nurse
specialists to assist with coordination and implementation of
evidence-based anaemia-based protocols are potential path-
ways to improve care delivery.
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